NCT06140290View on ClinicalTrials.gov

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions

Healthy Participants

Interventions

DRUG

Etrasimod Immediate Release (IR)

An immediate release tablet

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY